Drug Development Services for Brain Tumors

We offer small-molecule drug development services for brain tumors. Our R&D team has outstanding expertise in small molecule drug discovery for brain tumors, including theoretical computationally oriented structure design, target binding kinetics, and oncology studies. In addition, we are actively pursuing strategies that combine immunotherapy and small-molecule targeted therapies for the treatment of brain tumors.

Although treatment options for brain tumor patients remain very limited, the molecular targeting of brain tumors is very complex. However, as a leader in this field, we are not giving up on bringing more therapeutic pathways to our customers in the brain tumor field. In addition to small molecule drugs and immunotherapy, we are also deeply involved in the field of targeted therapies. We are ready to help you find specific genes as promising targets for molecularly targeted brain tumor therapy.

Antibody-mediated immunotherapy is an important tool for the immunotherapy of brain tumors. We aim to provide our customers with antibody development services for brain tumors through our proven technology platform. To expand the audience for antibody drugs, we are actively conducting antibody drug miniaturization studies. We are trying to obtain Fab fragments, single-chain antibodies, bispecific antibodies, trivalent antibodies, and miniature antibodies by enzymatic digestion or genetic engineering.

Exosomes readily cross the blood-brain barrier into and out of the central nervous system. Exosomes are not only a new biomarker assay, but also provide potential molecular therapeutic targets that hold promise as vehicles for anti-brain tumor drug delivery. We can detect specific sequence changes in DNA isolated from brain tumor patient samples to identify potential biomarkers. We are also developing exosomes as an interventional target for immunotherapy.

Our services include brain tumor stem cell analysis, circulating tumor cell assays, rare cell analysis, cell microarrays, and quantitative DNA analysis of brain tumor cells. At the tissue level, we offer tissue microarrays as well as organoid and organ microarray services. Of course, we also have extensive experience in brain tumor-specific gene analysis, genomics, spatial transcriptomics, metabolomics, proteomics, imaging omics, genetic analysis, and gene microarrays.

The purpose of preclinical studies is to provide preliminary testing of drug safety issues. Sometimes, preclinical studies can also provide some relevant information about the efficacy of a drug and lay the foundation for human trials of the drug. We help you capture potential opportunities and make early and informed decisions to maximize the likelihood of successful clinical studies with our brain tumor in vitro assay services, model-building services, and cell line development services.